Clinical trials: Allergy; Dermatitis
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant…
- Trial name
- GLOBOSTAD (NCT03992417)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 105 sites in Argentina, Australia and 20 more
- Volunteers
- 955 people
- Sponsor
- Sanofi
Allergic Contact Dermatitis
Allergy Skin Patch Artificial Intelligence (AI)
The purpose of this research is to assess human and artificial intelligence performance in grading contact dermatitis reactions in healthy volunteers.
- Trial name
- NCT05339750
- Testing
- AI-based smartphone application, Allergen patch
- Where
- United States
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Colorectal Cancer, Gastric Cancer (GC)
Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS)
Hand-foot syndrome (HFS) is a frequent adverse effect of capecitabine, presenting with redness, swelling, pain, and peeling of the skin on the palms and soles.
- Conditions
- Colorectal Cancer, Gastric Cancer (GC), Capecitabine, Hand Foot Syndrome
- Trial name
- DICLO-HFS (NCT07177560)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 151 people
- Sponsor
- Gazi University
Dermatitis
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
- Trial name
- NCT01259323
- Testing
- REGN668
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
This is a Multicenter, Randomized, Double-blind, Placebo-controlled seamless and adaptive-designed phase IIb/III study to Assess the Efficacy and Safety of topical use of PG-011 Gel in adolescents and Adults With Atopic…
- Trial name
- NCT06587685
- Testing
- PG-011Gel, Vehicle
- Where
- China
- Volunteers
- 472 people
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Adolescents With Moderate-to-severe Atopic Dermatitis
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07309055
- Testing
- SHR-1819 Injection
- Where
- 2 sites in China
- Volunteers
- 201 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Dermatitis, Atopic
Efalizumab for Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine if Raptiva will have beneficial effects in the treatment of patients with moderate to severe atopic dermatitis.
- Trial name
- NCT00226057
- Testing
- Raptiva
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Atopic Dermatitis
Prenatal Exposure to Emerging Contaminants and Children's Atopic Dermatitis
This prospective cohort study aims to investigate the association between prenatal blood levels of Emerging Contaminants and the five-year incidence of atopic dermatitis (AD) in offspring.
- Trial name
- PECCAD (NCT06316609)
- Testing
- Gestational Exposure to Emerging Contaminants (ECs)
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Children's Hospital of Fudan University
Psoriasis, Eczema/Atopic Dermatitis
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases
Psoriasis, atopic dermatitis (eczema) and hidradenitis suppurativa are long-term skin conditions that flare and settle over time. Most of what happens to the skin happens at home, between hospital appointments.
- Conditions
- Psoriasis, Eczema/Atopic Dermatitis, Hidradenitis Suppurativa (HS)
- Trial name
- Skin-in-Sight (NCT07804134)
- Where
- 3 sites in Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Medisch Spectrum Twente
Atopic Dermatitis
A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis
This study will describe safety of dupilumab in adult participants with atopic dermatitis. It will also look at the improvement of atopic dermatitis signs and symptoms in these participants.
- Trial name
- NCT07905547
- Testing
- Dupilumab
- Volunteers
- 56 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at…
- Trial name
- ROCKET-SHUTTLE (NCT05724199)
- Testing
- Rocatinlimab
- Where
- 234 sites in United States, Argentina and 24 more
- Volunteers
- 746 people
- Sponsor
- Amgen
Atopic Dermatitis (AD)
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
The purpose of this study is to understand the effect that T helper 2 (Th2) blockade has on well-described pathophysiological features of Atopic Dermatitis (AD), for example: barrier, epidermal activation, dysbiosis and epidermal…
- Trial name
- NCT03389893
- Testing
- Dupilumab
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.
- Trial name
- NCT00125333
- Testing
- NF-kappaB Decoy
- Where
- 9 sites in United States
- Volunteers
- 75 people
- Sponsor
- Anesiva, Inc.
Atopic Dermatitis
Atopic Dermatitis Cutaneous Discomfort of the Infant Under the Age of One Year : Analysis of Filmed Sequences (PRE-PRURINEO)
Analysis of filmed sequences for the assessment of discomfort in atopic dermatitis in infants under 1year of age
- Trial name
- PRE-PRURINEO (NCT06551363)
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Brest
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Stevens-Johnson Syndrome, Corneal Blindness
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on…
- Trial name
- NCT01256489
- Testing
- Infliximab
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary
Dermatitis, Atopic
Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
Part A To measure and compare the amount of study drug in the blood after a single 200 mg dose of study drug given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions To measure and…
- Trial name
- NCT04065633
- Testing
- P3-Fast, Comm-Fast, Vari-Fast
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dermatitis Atopic
A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries
Primary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment.
- Trial name
- AD-impaCT (NCT05214326)
- Where
- 3 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 187 people
- Sponsor
- Sanofi
Atopic Dermatitis, Atopic Dermatitis Eczema
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
- Trial name
- NCT07734415
- Testing
- IMG-007
- Where
- 23 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Inmagene LLC
Atopic Dermatitis, Asthma
Prospective Longitudinal Observational Research in Atopic Dermatitis
Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life.
- Conditions
- Atopic Dermatitis, Asthma, Atopic Dermatitis and Related Conditions
- Trial name
- ProRaD (NCT04240522)
- Where
- Switzerland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Zurich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.